Dogwood Therapeutics, Inc. (DWTX)
| Market Cap | 50.44M +382.9% |
| Revenue (ttm) | n/a |
| Net Income | -28.32M |
| EPS | -2.18 |
| Shares Out | 33.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 49,918 |
| Open | 1.610 |
| Previous Close | 1.680 |
| Day's Range | 1.500 - 1.640 |
| 52-Week Range | 1.280 - 9.500 |
| Beta | 1.70 |
| Analysts | Buy |
| Price Target | 14.00 (+827.15%) |
| Earnings Date | May 14, 2026 |
About DWTX
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended t... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for DWTX stock is "Buy." The 12-month stock price target is $14.0, which is an increase of 827.15% from the latest price.
News
Dogwood begins Phase 2b extension study for Halneuron
Dogwood (DWTX) Therapeutics announced commencement of a new Halneuron chemotherapy induced neuropathic pain phase 2b extension study. “Neuropathic pain is a difficult to treat chronic condition, as ev...
Dogwood Therapeutics Announces Commencement of Halneuron® Chemotherapy Induced Neuropathic Pain Phase 2b Long Term Extension Study
New study to assess Halneuron ® pain reduction effect over three months of treatment, additional safety data to bolster planned end of Phase 2 FDA submission package
Dogwood Therapeutics Earnings release: Q1 2026
Dogwood Therapeutics released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Dogwood Therapeutics Quarterly report: Q1 2026
Dogwood Therapeutics has published its Q1 2026 quarterly earnings report on May 14, 2026.
Dogwood Therapeutics Announces First Quarter 2026 Financial Results
- Halneuron ® Phase 2b trial in Chemotherapy Induced Neuropathy on track for top-line results in fall 2026 -
Dogwood Therapeutics Slides: Corporate presentation
Dogwood Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026
ATLANTA, May 07, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a company that focuses on developing new medicines to treat pain and neuropathy, today...
Dogwood Therapeutics Proxy statement: Proxy filing
Dogwood Therapeutics filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood announces commercialization partnership with PRIDCor
Dogwood (DWTX) announced a global development and commercialization partnership with PRIDCor Therapeutics, a clinical-stage biopharmaceutical company developing antiviral therapies for infection-assoc...
Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M
- PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, including Fibromyalgia and Long-COVID - - Dogwood Granted a Tiered Royal...
Dogwood Therapeutics Proxy statement: Proxy filing
Dogwood Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood announces FDA acceptance of SP16 investigational new drug application
Dogwood (DWTX) announced FDA acceptance of an investigational new drug application for its development candidate SP16, administered intravenously, for the treatment of chemotherapy-induced pain and pe...
Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected...
Dogwood Therapeutics Annual report: Q4 2025
Dogwood Therapeutics has published its Q4 2025 annual report on March 18, 2026.
Dogwood Therapeutics Earnings release: Q4 2025
Dogwood Therapeutics released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Dogwood sees cash runway into 4Q26
As of December 31, 2025, Dogwood (DWTX) Therapeutics’ cash and cash equivalents totaled $6.5 million. The Company believes that the cash and cash equivalents on hand at December 31, 2025…
Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, ...
Dogwood Therapeutics Proxy statement: Proxy Filing
Dogwood Therapeutics filed a proxy statement on February 13, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial
Dogwood (DWTX) Therapeutics announced it has achieved over 50% of the planned enrollment in its ongoing HAL-CINP-203 Phase 2b chemotherapy induced neuropathic pain, HALT-CINP, trial. HALT-CINP remains...
Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026
- Low early termination rate (4.3%) among the first 116 patients completing the study suggests Halneuron ® treatment to be well tolerated - ATLANTA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeut...
Dogwood Therapeutics Slides: Investor presentation
Dogwood Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on January 26, 2026.
Dogwood Therapeutics Proxy statement: Proxy Filing
Dogwood Therapeutics filed a proxy statement on January 23, 2026, providing details for shareholder voting and corporate governance matters.
Dogwood files to sell 6.43M shares of common stock for holders
16:22 EST Dogwood (DWTX) files to sell 6.43M shares of common stock for holders
Dogwood Therapeutics Registration statement: Registration Filing
Dogwood Therapeutics filed a registration statement on January 15, 2026, providing details about a securities offering with the SEC.
Dogwood announces financing of up to $26.8M
Dogwood (DWTX) Therapeutics has entered into a securities purchase agreement with a single healthcare-focused institutional investor for up to approximately $12.5 million in gross proceeds through a r...